Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: A UK dual centre experience

Transfusion Medicine

Volumn 25, Issue 6, 2015, Pages 418-423

  Hall, S ^a   Danby, R ^b   Osman, H ^c   Peniket, A ^b   Rocha, V ^b   Craddock, C ^c   Murphy, M ^a   Chaganti, S ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Allogeneic stem cell transplant; Cytomegalovirus; Leukocyte reduction; T cell depletion; Transfusion

Indexed keywords

ALEMTUZUMAB; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD COMPONENT; BLOOD TRANSFUSION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POLYMERASE CHAIN REACTION; T CELL DEPLETION; UNITED KINGDOM; VIRUS TRANSMISSION; ALLOGRAFT; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTIONS; LYMPHOCYTE DEPLETION; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; TRANSMISSION;

ADOLESCENT; ADULT; AGED; ALLOGRAFTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; UNITED KINGDOM;

EID: 84983099932     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/tme.12219     Document Type: Article

References (23)

1. Advisory committee on the safety of blood, tissues and organs (2012) Report of the cytomegalovirus steering group. URL http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/215126/dh_132966.pdf (Accessed 9/2/2015).
2. Bowden, R.A., Slichter, S.J., Sayers, M. et al. (1995) A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood, 86, 3598-3603.
3. Chakrabarti, S., Mackinnon, S., Chopra, R. et al. (2002) High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood, 99, 4357-4363.
4. Drew, W.L., Tegtmeier, G., Alter, H.J., Laycock, M.E., Miner, R.C. & Busch, M.P. (2003) Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion, 43, 309-313.
5. George, B., Kerridge, I.H., Gilroy, N., Huang, G., Hertzberg, M.S., Bradstock, K.F. & Gottlieb, D.J. (2012) A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group. Transplant Infectious Diseases, 14, 141-148.
6. Greenlee, D.J., Fan, H., Lawless, K., Harrison, C.R. & Gulley, M.L. (2002) Quantitation of CMV by real-time PCR in transfusable RBC units. Transfusion, 42, 403-408.
7. Kekre, N., Tokessy, M., Mallick, R. et al. (2013) Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction? Biology of Blood and Marrow Transplantation, 19, 1719-1724.
8. Lamba, R., Carrum, G., Myers, G.D., Bollard, C.M., Krance, R.A., Heslop, H.E., Brenner, M.K. & Popat, U. (2005) Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplantation, 36, 797-802.
9. Narvios, A.B., Przepiorka, D., Tarrand, J., Chan, K.W., Champlin, R. & Lichtiger, B. (1998) Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients. Bone Marrow Transplantation, 22, 575-577.
10. Nash, T., Hoffmann, S., Butch, S., Davenport, R. & Cooling, L. (2012) Safety of leukoreduced, cytomegalovirus (CMV)-untested components in CMV-negative allogeneic human progenitor cell transplant recipients. Transfusion, 52, 2270-2272.
11. National Blood Service (2013) Guidelines for the Blood Transfusion Services in the UK (8th edn). The Stationery Office, London.
12. Nichols, W.G., Price, T.H., Gooley, T., Corey, L. & Boeckh, M. (2003) Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood, 101, 4195-4200.
13. Pennington, J., Garner, S.F., Sutherland, J. & Williamson, L.M. (2001) Residual subset population analysis in WBC-reduced blood components using real-time PCR quantitation of specific mRNA. Transfusion, 41, 1591-1600.
14. Roback, J.D., Drew, W.L., Laycock, M.E., Todd, D., Hillyer, C.D. & Busch, M.P. (2003) CMV DNA is rarely detected in healthy blood donors using validated PCR assays. Transfusion, 43, 314-321.
15. Schmidt-Hieber, M., Schwarck, S., Stroux, A., Ganepola, S., Reinke, P., Thiel, E., Uharek, L. & Blau, I.W. (2010) Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. International Journal of Hematology, 91, 877-885.
16. Thiele, T., Krüger, W., Zimmermann, K., Ittermann, T., Wessel, A., Steinmetz, I., Dölken, G. & Greinacher, A. (2011) Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation. Transfusion, 51, 2620-2626.
17. Vamvakas, E.C. (2005) Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfusion Medicine Reviews, 19, 181-199.
18. van, Burik, J.A., Carter, S.L., Freifeld, A.G. et al. (2007) Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biology of Blood and Marrow Transplantation, 13, 1487-1498.
19. van, Prooijen, H.C., Visser, J.J., van, Oostendorp, W.R., de, Gast, G.C. & Verdonck, L.F. (1994) Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. British Journal of Haematology, 87, 144-147.
20. Wu, Y., Zou, S., Cable, R. et al. (2010) Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion, 50, 776-786.
21. Zhang, C., Buchanan, H., Andrews, W., Evans, A. & Pass, R.F. (2006) Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding. Journal of Clinical Virology, 35, 338-342.
22. Ziemann, M., Heuft, H.G., Frank, K., Kraas, S., Görg, S. & Hennig, H. (2013a) Window period donations during primary cytomegalovirus infection and risk of transfusion-transmitted infections. Transfusion, 53, 1088-1094.
23. Ziemann, M., Juhl, D., Görg, S. & Hennig, H. (2013b) The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients. Transfusion, 53, 2183-2189.